{"id":"NCT04235140","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation","officialTitle":"A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-24","primaryCompletion":"2023-08-22","completion":"2023-08-22","firstPosted":"2020-01-21","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":52,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"LUM/IVA","otherNames":["lumacaftor/ivacaftor","VX-809/VX-770"]}],"arms":[{"label":"LUM/IVA","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, multicenter, open-label and roll-over study in participants who are 12 to \\<24 months of age at initiation of Lumacaftor/Ivacaftor (LUM/IVA) treatment.","primaryOutcome":{"measure":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 120","effectByArm":[{"arm":"LUM/IVA","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":23,"countries":["United States","Canada"]},"refs":{"pmids":["37983082","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":52},"commonTop":["Cough","Upper respiratory tract infection","Pyrexia","Rhinorrhoea","Constipation"]}}